<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03885596</url>
  </required_header>
  <id_info>
    <org_study_id>CA-PS-205</org_study_id>
    <nct_id>NCT03885596</nct_id>
  </id_info>
  <brief_title>Open-Label CA-008 in Bunionectomy</brief_title>
  <official_title>An Open-Label Study of Intraoperative CA-008 Administration in Subjects Undergoing Bunionectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concentric Analgesics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concentric Analgesics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, open-label study of CA-008 to evaluate post-surgical pain control with CA-008.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, single-center, open-label study evaluating a single dose of CA-008 4.2 mg
      administered during an elective unilateral transpositional first metatarsal osteotomy for the
      correction of hallux valgus deformity (bunionectomy).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 25, 2019</start_date>
  <completion_date type="Actual">October 22, 2019</completion_date>
  <primary_completion_date type="Actual">July 2, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-specific mean pain intensity scores Numerical Rating Scale scores (at rest and with ambulation) for CA-008 over the 72h inpatient stay</measure>
    <time_frame>At 72 hours</time_frame>
    <description>10 point numerical rating scale (NRS) - Scale is 0 to 10. 0 no pain and 10 worse possible pain</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Open-Label CA-008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CA-008 4.2 mg reconstituted in saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CA-008</intervention_name>
    <description>Drug: CA-008 4.2 mg reconstituted in saline</description>
    <arm_group_label>Open-Label CA-008</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult aged 18 - 65 years old

          2. American Society of Anesthesiology (ASA) physical Class 1, 2 or 3

          3. Planning elective Bunionectomy repair

          4. For both males and females: using an acceptable method of birth control

          5. If a female: not pregnant or breastfeeding

          6. Have a body mass index â‰¤ 36 kg/m2

        Exclusion Criteria:

          1. Have another painful condition, other than bunion-related pain, that may require pain
             treatment during the study period

          2. Have active skin disease or another abnormality at the anticipated site of surgery
             that could interfere with the planned surgery.

          3. Have a known allergy to study medications.

          4. Have a history of significant medical, neuropsychiatric or other condition, including
             a clinically significant abnormal clinical laboratory test values

          5. Have positive results on the alcohol test (breath or saliva) or urine drug screen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Royal, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Concentric Analgesics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lotus Clinical Research, LLC</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

